Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.

Integrating genetic testing into routine oncology care in the UK

Dr Joslyn Ngu
04 Dec 2017

Making genetic testing mainstream, allows more patients to be tested, identifies more carriers and enables appropriate stratification of treatment and outcomes, says an expert.

Despite the many advantages of genetic testing, patients with ovarian cancer are historically under-referred, said Dr Angela George, consultant oncogenetics and clinical lead of the Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, UK. The reasons for this include the failures to take family history; to recognize family history; and to refer.

The integration of genetic testing into routine oncology care requires the education of clinicians, oncologists and specialized nurses so they are well-equipped to take consent from patients for genetic testing, said George. Once patients who fit the pre-agreed criteria for testing gives their consent, healthcare professionals in the clinic can obtain the necessary blood samples and send them together with the forms to a genetics centre. This will reduce the need for patients to make additional appointments with the genetics department, which means no extra appointments and no waiting for referral, she said.

In the UK, a training programme for healthcare professionals to perform BRCA gene testing for breast and ovarian cancer is available on Youtube and a certificate of completion is provided, said George.

Ovarian cancer is a good example to showcase the benefits of mainstreaming genetic testing. An estimated 15 percent of ovarian cancer have a BRCA 1 or BRCA 2 mutation. [Sci Rep 2016;6:29506. Doi: 10.1038/srep29506]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.